New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences

More documents

Recommendations

Info

2 nd Annual Essentials in Primary Care Fall Conference Friday, November 11, 2011 Liraglutide – Victoza Pancreatitis: Warnings and Precautions • In five clinical trials including more than 3,900 people, there were seven cases of pancreatitis in patients using liraglutide and one case in a patient using another diabetes medicine. This constituted a 4:1 imbalance of pancreatitis cases, when considering the number of patient exposures (2.2 vs. 0.6 cases per 1000 patient-years). • Patients taking liraglutide should be aware of the symptoms of pancreatitis, such as severe abdominal pain that may also radiate into the back, possibly with nausea, and vomiting. Liraglutide – Victoza Adverse Effects in Clinical Trials %__ • Nausea 28.4 • Diarrhea 17.1 • Vomiting 10.9 • Constipation 9.9 • Upper Respiratory Tract Infection 9.5 Wayne Weart New Drug Update Part I
2 nd Annual Essentials in Primary Care Fall Conference Friday, November 11, 2011 Liraglutide – Victoza Linagliptin – Tradjenta by Boehringer Ingelheim and Lilly • A dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus • The recommended dose of linagliptin is 5 mg once daily with or without food. • Cost $243.60/30 tablets AWP Wayne Weart New Drug Update Part I
Page 1 and 2: 2 nd Annual Essentials in Primary C
Page 17: 2 nd Annual Essentials in Primary C
Page 69 and 70:
2 nd Annual Essentials in Primary C
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77:
show all

New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences

Create successful ePaper yourself

Delete template?

Save as template?